Efficacy and Safety of IL-12, IL-17, IL-12/23, and IL-23 Inhibitors for Moderate-to-Severe Psoriasis: A Systematic Review and Bayesian Network Meta-Analysis

Taltz (ixekizumab) - Eli Lilly

Bimzelx (bimekizumab-bkzx) - UCB

Ilumya (tildrakizumab-asmn) - Sun Pharma, Almirall

Stelara (ustekinumab) - J&J

Siliq (brodalumab) - Bausch Health

Khalid Alshareef 1; Maria Alsulami2; Abdullah Alqthmi3; Raneem Alahmadi2; Khalid Basamih3; Aymen Hamed Alharbi 4; Sarah Alsukait5

May 13, 2026